Pangaea Oncology S.A. Asset Resilience Ratio
Pangaea Oncology S.A. asset resilience ratio. Pangaea Oncology S.A. (PANG) has an Asset Resilience Ratio of 3.42% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PANG defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pangaea Oncology S.A. (2013–2025)
Asset resilience ratio of Pangaea Oncology S.A. from 2013 to 2025. This chart shows how Pangaea Oncology S.A.'s Asset Resilience Ratio has changed over time. Read Pangaea Oncology S.A. (PANG) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pangaea Oncology S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Pangaea Oncology S.A..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.10 Million | 3.42% |
| Total Liquid Assets | €1.10 Million | 3.42% |
Asset Resilience Insights
- Limited Liquidity: Pangaea Oncology S.A. maintains only 3.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pangaea Oncology S.A. Industry Peers by Asset Resilience Ratio
Compare Pangaea Oncology S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Pangaea Oncology S.A. Asset Resilience Ratio by Year (2013–2025)
Pangaea Oncology S.A. asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Pangaea Oncology S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.42% | €1.10 Million ≈ $1.28 Million |
€32.11 Million ≈ $37.54 Million |
+0.04pp |
| 2024-12-31 | 3.39% | €1.10 Million ≈ $1.28 Million |
€32.41 Million ≈ $37.89 Million |
-1.50pp |
| 2023-12-31 | 4.88% | €1.41 Million ≈ $1.65 Million |
€28.83 Million ≈ $33.71 Million |
-25.12pp |
| 2022-12-31 | 30.01% | €8.51 Million ≈ $9.95 Million |
€28.38 Million ≈ $33.18 Million |
+15.94pp |
| 2021-12-31 | 14.06% | €2.93 Million ≈ $3.43 Million |
€20.85 Million ≈ $24.38 Million |
+12.32pp |
| 2020-12-31 | 1.75% | €299.85K ≈ $350.55K |
€17.17 Million ≈ $20.08 Million |
-3.15pp |
| 2019-12-31 | 4.90% | €826.59K ≈ $966.37K |
€16.88 Million ≈ $19.73 Million |
+1.20pp |
| 2018-12-31 | 3.69% | €751.56K ≈ $878.65K |
€20.35 Million ≈ $23.79 Million |
-1.60pp |
| 2017-12-31 | 5.30% | €1.00 Million ≈ $1.17 Million |
€18.96 Million ≈ $22.16 Million |
+2.91pp |
| 2016-12-31 | 2.39% | €428.47K ≈ $500.93K |
€17.94 Million ≈ $20.97 Million |
+2.08pp |
| 2015-12-31 | 0.31% | €34.34K ≈ $40.15K |
€11.01 Million ≈ $12.87 Million |
+0.29pp |
| 2014-12-31 | 0.02% | €1.75K ≈ $2.05K |
€8.46 Million ≈ $9.89 Million |
-0.04pp |
| 2013-12-31 | 0.06% | €3.75K ≈ $4.38K |
€6.54 Million ≈ $7.64 Million |
-- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling a… Read more